The FDA has approved the two human mAbs Ipilimumab and Tremelimumab (Figure 1), which bind to CTLA-4 specifically, thereby blocking their interaction with B7.1 and B7.2, leading to antitumor immune response induction against various types of tumor cells. This evidence concerns the gene CD86 and neoplasm.